Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $42.09, for a total transaction of $1,052,250.00. Following the sale, the chief executive officer owned 1,348,095 shares of the company’s stock, valued at approximately $56,741,318.55. The trade was a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total transaction of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The stock was sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Price Performance

Shares of Liquidia stock traded up $0.14 during trading on Thursday, hitting $42.28. 1,196,501 shares of the company were exchanged, compared to its average volume of 1,625,170. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $46.67. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of -50.94 and a beta of 0.41. The firm has a 50 day moving average price of $36.79 and a 200 day moving average price of $34.57.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The firm had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. The firm’s quarterly revenue was up 3072.4% compared to the same quarter last year. On average, equities analysts expect that Liquidia Corporation will post 1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Wells Fargo & Company lifted their price objective on Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Monday, March 23rd. HC Wainwright lifted their target price on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Jefferies Financial Group lifted their target price on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and an average target price of $43.44.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. grew its stake in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after acquiring an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after acquiring an additional 16,022 shares during the period. Creative Planning grew its stake in Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Liquidia by 13.4% during the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after buying an additional 11,111 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).